Orladeyo Approval for HAE Under Review in Canada, Switzerland

Orladeyo Approval for HAE Under Review in Canada, Switzerland

304407

Orladeyo Approval for HAE Under Review in Canada, Switzerland

Regulatory health agencies in Canada and Switzerland are reviewing BioCryst Pharmaceuticals’ applications for the approval of Orladeyo (berotralstat) in their countries for preventing hereditary angioedema (HAE) attacks in patients ages 12 and older. The applications — to Heath Canada and Swissmedic — followed Orladeyo’s recent approvals in the U.S., the European Union, and other countries as the first oral treatment to prevent HAE attacks. “We are making significant progress with our goal to bring Orladeyo…

You must be logged in to read/download the full post.